• Oncology-related deaths are the second leading cause of mortality worldwide, with 8.2 million deaths in 2012. 1 Moreover, the number of new cancer cases is expected to further increase by 70% over the next two decades. 2
INTRODUCTION RESULTS
• Seven value frameworks were identified and considered relevant for detailed evaluation. These frameworks, their target audiences, and key points of critique, collected from a review of the literature and opinion papers, are listed in Table 1 . The value items considered in each framework are summarized in Table 2 .
• All frameworks aim to provide an objective assessment of the value of anti-cancer therapies, but vary in their definition of value, methodology, target audience, and stage of development.
− Similarities of the frameworks include: aiming to assess treatment value in a transparent and objective manner, safety and clinical efficacy being vital elements, and patient preference and quality of life not being included or given much weight.
− Differences include: stage of development, target audience, methodology, and value dimensions and items.
PASKWIL

Background
• PASKWIL is an acronym derived from the five dimensions of the tool: Palliative/Adjuvant effectiveness, Specific adverse events, (Kw) quality of life, Impact of treatment, and Level of evidence.
• Established in 2000 in the Netherlands, the criteria were revised in 2012 4, 5 due to the range of oncology drugs, heterogeneous indications, and reported end points.
Method
• The framework uses available data to evaluate if a drug meets the pre-specified PASKWIL criteria (dichotomous outcome + or -).
CDF Prioritisation Tool
Background
• The Cancer Drugs Fund (CDF) was established in 2011 to provide patients in England with access to anti-cancer drugs that are not routinely available within the National Health Service, due to their not being appraised by the National Institute for Health and Care Excellence (NICE), not being recommended by NICE, or being used in non-licensed indications or formulations.
• The framework has helped .70,000 cancer patients gain access to treatments that may otherwise have been denied them, but questions remain regarding its ethical basis and cost, leading to a number of drugs being removed from the list.
Method
• The CDF Prioritisation Tool 6 assesses the degree of clinical benefit provided by anti-cancer drugs for a specific indication.
• The assessment is based on a number of attributes (and their scores) to give an overall score: diseasefree survival, progression-free survival (PFS), time-to-progression gains (0 to 13); overall survival (OS) benefit (0 to 13); quality of life (-2 to 2); toxicity (-2 to 2); unmet need (0 to 3); and strength of evidence (Grade A to U2).
ESMO Magnitude of Clinical Benefit Scale
Background
• In 2015, ESMO developed the Magnitude of Clinical Benefit Scale 7 as a framework to assess each new anti-cancer drug approved by the European Medicines Agency.
• Drugs that obtain the highest scores will be emphasized in the ESMO guidelines, but the target audience extends to public policy-makers.
Method
• Drugs are assigned a clinical benefit grade, ranging from A to C in the curative/adjuvant setting, and 1 to 5 in the non-curative setting. 7 • In the curative/adjuvant setting, only efficacy measures such as OS and disease-free survival are taken into consideration.
• In the non-curative setting with OS or PFS as the end point, efficacy results are used to derive a preliminary magnitude of clinical benefit (1 to 4) that can be upgraded or downgraded by one level based on the quality of life and/or toxicity outcomes.
ASCO Conceptual Framework
Background
• Since 2013, ASCO's Value in Cancer Care Task Force has been developing a conceptual framework to assess the relative value of new cancer therapies in comparison with the current standards of care. 8 • The Task Force aims to provide medical oncologists with a physician-guided tool to assess the relative value of cancer therapies as an element of shared decision-making with their patients.
Method
• Three elements are considered: efficacy, safety, and efficiency.
• The framework calculates a net health benefit score by awarding or subtracting points for clinical benefit (efficacy) and toxicity (safety), and comparing these with the direct treatment costs (efficiency) to provide an overall assessment score.
• There are two versions of the tool, one for non-curative/advanced cancers (scored out of 130) and the other for potentially curative treatment (scored out of 100).
• Treatments can score up to 80 points for efficacy benefits (OS, PFS, or response rate). A drug may gain an additional 20 points if it is substantially better tolerated than its comparator.
• In the non-curative/advanced setting, a drug can gain an additional 10 points for palliation of symptoms, and 20 points for statistically significant improvement in treatment-free interval.
NCCN Evidence Blocks
Background
• In October 2015, the NCCN in the United States unveiled its NCCN Evidence Blocks value initiative that would serve as a starting point for shared decision-making based on the individual patient's value system. 9 • Five key measures are: efficacy, safety, quantity and quality of evidence, consistency of evidence, and affordability.
Method
• Panel members score each of the five measures using a standardized scale, 1 (least favorable) to 5 (most favorable), that are used to generate the Evidence Blocks.
• The Evidence Blocks are placed on the NCCN Guidelines algorithm, allowing appropriate interventions to be scanned, and treatment recommendations to be made, based on what is most important to the patient.
• Resulting data are analyzed, and final scores based on the responses from all panel members are rounded to the nearest whole number and presented in 5  5 tables.
• Each column in the Evidence Block corresponds to one of the key five measures and is shaded from bottom to top representing the corresponding score for each measure.
MSKCC DrugAbacus
Background
• An interactive online tool, DrugAbacus, was developed in 2015 by the Memorial Sloan Kettering Cancer Center in New York to help physicians and policy-makers decide to what degree a series of factors should be related to a drug's value.
• The tool is aimed at policy-makers to explore the idea of finding fair prices for drugs, while respecting the complexity and subjectivity of what "value" means. 10
Method
• The tool measures six attributes (based on clinical data and expert opinion): efficacy, tolerability, novelty, research and development costs, rarity, and population burden. 11 • The user can set the relative contribution of these attributes, within a pre-determined range of possible values, to the DrugAbacus price. 12 For efficacy, the gain in OS is multiplied by the user-defined dollar value per life-year, to obtain the initial efficacy value that multipliers for the five other attributes are applied to.
• The tool calculates a price for 54 recently approved cancer drugs based on objective clinical data, allowing comparisons to be made with their initial market prices.
ICER Value Assessment Framework
Background
• The Institute for Clinical and Economic Review (ICER) provides independent health care technology assessment reports on drugs, devices, and other medical services in the United States. These reports are increasingly being used by health insurers to inform their formulary listing decisions.
• In September 2015, an ICER Value Assessment Framework was introduced, linking the institution's approach for calculating a "reasonable" price for treatments.
• The scope of the framework is not limited to oncology and can be applied to other therapeutic areas.
Method
• The framework includes two broad components:
− Care value: comprising comparative effectiveness and incremental costs per clinical outcome achieved.
− Health system value: which assesses the short-term budget impact.
• The framework is used to calculate a range related to the price that a new drug would meet costeffectiveness thresholds of $100,000 and $150,000.
• Treatments with an incremental cost ratio below $100,000 are considered high-value care and those exceeding $150,000 are deemed low-value care. 13 • Treatment is assessed as to whether the drug's potential budget impact would stay below $904 million per year when annualized over a 5-year period. This budget impact threshold is twice the average available for any new drug.
Summary of framework limitations
• Treatment "value" is an indefinable target and there is no consensus regarding what dimensions should be taken into account, how they should be incorporated into the tool (e.g. additive vs multiplicative scoring), or how much weight should be given to each. 8, 14 • Although clinical efficacy and safety are key outcomes, many frameworks can only use results from comparative randomized controlled trials and do not consider data from single-arm studies or real-world evidence. 7, 8, 15, 16 • Of note, the majority of the frameworks have been criticized for not being sufficiently patient-centered, as quality-of-life measurements, patient-reported outcomes, and the preferences and needs of patients are rarely considered or given little weight. 8, [15] [16] [17] [18] [19] • When determining "value for money", many tools focus only on drug acquisition costs. Consequently, any potential treatment-related benefits to the health care system (e.g. avoidance of diagnostic tests and interventions) or wider society (e.g. reduced loss in productivity) are not considered. 20 • While not necessarily designed to inform payer decision-making, there is concern that frameworks may be used to limit treatment access as a way of controlling drug costs. 21 This may limit the possibilities for a physician to tailor care to the individual patient's needs.
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CONCLUSIONS
• A number of health-related and professional organizations have launched frameworks designed to assess the value of oncology drugs.
• These frameworks vary in terms of their definition of value, target audience, methodology, and stage of development.
• Each of the frameworks has a number of limitations, which should to be taken into consideration when interpreting its outputs.
• It remains to be seen whether the different approaches will converge in the future, but harmonization would help to limit confusion and aid stakeholders in making informed decisions in cancer patient care. • Decision-making about which drugs should be included in the CDF is not transparent 25 • Bypasses and undermines NICE. Inefficient to assess the same drugs twice 25 • May be seen as prioritizing cancer at the expense of other therapeutic areas 26 • Arbitrarily derived values associated with different dimensions do not necessarily produce a coherent overall score 22 ESMO Magnitude of Clinical Benefit Scale 7
Overview and comparison of frameworks for the valuation of oncology drugs
Europe 2015
Doctor Patient Payer Policymaker
• Can only be applied to comparative outcomes from RCTs; not applicable when evidence derives from single-arm or real-world evidence studies 7, 16 • Validity of results may be influenced by quality and design of the study; e.g. a relatively weak control arm may generate exaggerated benefit of the experimental drug 7 • Relative weighting of evidence and thresholds for hazard ratio and absolute gains involves judgments and subjective considerations which are open to dispute and challenge 7 • Rankings are based on expert opinion only. Preferences of patients, family, or general public are not considered. Explicit measures of QoL from patient perspective are lacking 19, 24 • Developed only for solid tumors 7 • Does not consider any cost-related information as part of the evaluation 16 ASCO Conceptual Framework 8 USA 2015
• Scoring categories for OS, PFS, and response rate are somewhat arbitrary and weights are based largely on expert clinical opinions 8, 21 • Summing arbitrarily derived values associated with different dimensions does not necessarily produce a coherent overall score 22 • Derived from RCTs directly comparing two or more regimens and, hence, does not permit cross-trial comparisons 8, 15, 27 • QoL outcomes are excluded and patient preferences are not accounted for [16] [17] [18] • NHB scores may be inaccurate due to a lack of peer-reviewed publications, non-randomized trial designs, median OS or PFS not reached at the time of final analysis, and palliation or treatment-free interval data that are not available 28 • Drug pricing is set at launch, whereas demonstrated value will change over the product's life cycle 16, 23 NCCN Evidence Blocks 29 
USA 2015
• Evidence Blocks use OS as primary end point in determining efficacy, when PFS and improved QoL are important measures not considered by the tool 30 • Scores reflect a standardized view based on the "average patient" even though the circumstances for each cancer patient may differ significantly 30 • A patient's insurance policy and ability to pay for a specific treatment can be unique, and it is unclear how affordability based on average costs of various clinical items can be made relevant to an individual patient 21, 27, 30 • Payers may use the value assessment provided in the Evidence Blocks to justify coverage decisions 30 
MSKCC DrugAbacus 11
USA 2015
• Lacks some potentially important information, such as how patients describe their experience with the treatment 10 • A strategy setting prices to reflect research, development, and production costs for drugs does not reflect value or patient preferences 22 • It remains unclear how the various domain measurements have been derived from clinical trial data. For instance, the data do not contain any information about the probability of discontinuing drug use which is used for the toxicity attribute 31 • Drug manufacturers might consider increasing the prices of drugs considered by DrugAbacus to be excellent value for money 21 • Currently, only shows information for the first FDA-approved indication 27 ICER Value Assessment Project 13 USA 2015
• Limits each drug's budget impact to an arbitrary value of $904 million annually. The budget criterion used has little to do with patient benefit and may discourage companies from developing drugs designed to help significant numbers of patients 20, 22 • A 5-year time horizon is considered in the Value Framework's "Health System Value" metric, so long-term benefits and cost off-sets of some therapies may be undervalued 20, 32 • Methods used to assess the value of a therapy are based on a QALY benchmark, the disadvantages of which are well documented 20 • The data on which the "Health System Value" metric is based is not evidence-based, nor does it accurately reflect the realities of the marketplace 20 • Economic benefits such as improvements in worker productivity or reductions in caregiver burden are not taken into consideration 20 *Critiques were derived from the literature and are those of the authors but not necessarily those of the companies they work for. 
